Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Recruiting1

Clinical Trials (1)

Research Network

Active Sponsors

  • Duke University1
  • National Heart, Lung, and Blood Institute (NHLBI)1
  • University of Pennsylvania1

Top Investigators

Related Conditions

  • Lung Transplant Rejection1
  • Lung Transplant Complications1
  • Lung Transplant Failure1

Activity Timeline